Genomic Health's (GHDX) Oncotype DX(R) Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients
Up)
Genomic Health, Inc. (Nasdaq: GHDX) announced positive results from the landmark QUASAR validation study, which demonstrated that the Oncotype DX(R) colon cancer test can independently predict individual recurrence risk in stage II colon cancer patients following surgery. Importantly, the Oncotype DX colon cancer Recurrence Score(R) provided additional independent clinical value beyond standard measures. The study showed that the colon cancer Recurrence Score maintained significance (p=0.008), independent of mismatch repair (MMR), also known as MSI (Microsatellite Instability), T-stage, nodes examined, grade and lymphovascular invasion.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Nymox Pharmaceutical (NYMX) Reports Statistically Significant Data for NX-1207 in BPH
- Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
